Formulations of bendamustine

  • US 10,052,385 B2
  • Filed: 02/14/2017
  • Issued: 08/21/2018
  • Est. Priority Date: 03/20/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating chronic lymphocytic leukemia or indolent B-cell non-Hodgkin'"'"'s lymphoma in a subject in need of treatment comprising:

  • parenterally administering to the subject, over a period of less than or equal to about 15 minutes, about 100 ml or less of a liquid composition comprising;

    0.96-5.59 mg/mL of bendamustine or a pharmaceutically acceptable salt thereof;

    3.8-22.4 vol % of a nonaqueous component comprising polyethylene glycol and propylene glycol;

    a parenterally acceptable diluent; and

    optionally an antioxidant.

View all claims

    Thank you for your feedback